|Bid||30.90 x 800|
|Ask||32.00 x 200|
|Day's Range||30.95 - 31.69|
|52 Week Range||29.39 - 45.87|
|PE Ratio (TTM)||25.38|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||40.67|
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.
Mylan (MYL) and Theravance Biopharma plan to file an NDA seeking approval from the FDA for investigational drug revefenacin for COPD in 2017.
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.